Herbal Drugs Analysis

Herbal Drugs Analysis
Product Description

Since 2018 Brightlabs possesses an opium exemption from the BMC (Bureau for Medicinal Cannabis), for the analysis of cannabis and related products. The combination of this opium exemption, combined with our GMP accreditation, makes Brightlabs an important partner for the analysis of cannabis and related materials for both the Pharma-, Food-, and supplements sector. By now we have ample experience with both the analysis of CBD products such as oil and candy, as the analysis of pharmaceutical products, ranging from hand sanitizer to medicinal cannabis in conformity with the current Pharmacopoeia

Brightlabs

  • NL
  • 2021
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Contract Service
Specifications

Brightlabs

  • NL
  • 2021
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Contract Service

More Products from Brightlabs (3)

  • Elemental Impurities

    Product Elemental Impurities

    Brightlabs has in-house validated methods for the analysis of elemental impurities in accordance to ICH-Q3D. Brightlabs has a unique approach for ICHQ3D, which guarantees quick turnaround times at reduced cost
  • Method Development

    Product Method Development

    We are specialist in the method development of analytical methods for analysis of API, Final Drug Products or low level impurities. Usually followed by full validation in accordance to ICH guidelines.
  • Nitrosamine Analysis

    Product Nitrosamine Analysis

    In response to nitrosamines present in pharmaceutical products, the European Medical Agency (EMA) and the US Food and Drug Administration (US FDA) have published requirements and limits related to nitrosamine contaminants. Therefore Brightlabs has developed and validated multiple methods to determine low l...

Brightlabs resources (1)

  • Brochure NDSRI analysis

    Brightlabs has developed and validated multiple methods (GC-MS/MS & LC-MS/MS) to determine low level concentrations of Nitrosamines and NDSRIs in Drug Products